Archived explainer. For the current picture see today's NVO page.
Why Is NOVO-NORDISK A S ADR (NVO) Stock Down Today?
By the Top Tier Newswire AI Desk · July 31, 2026 at 9:42 AM ET · reviewed against 15 wire stories
NOVO-NORDISK A S ADR (NVO) is down -9.00% in the latest session. Our newswire has captured 15 stories on NVO across 12 sources in the last 36 hours, with AI sentiment reading bearish (avg 37/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why NVO stock is down today
Novo Nordisk A/S ADR (NVO) fell 9.00% in the session to $46.94 after the company announced that its late-stage trial for the investigational drug ziltivekimab failed to meet its primary endpoint. The Phase 3 trial showed that the drug did not reduce major adverse cardiovascular events compared with a placebo. The stock opened with a 2.0% gap down and continued to decline throughout the session, reaching a low of $45.36 before closing near $46.97.
What Happened
The decline follows the announcement that ziltivekimab, Novo Nordisk’s anti-inflammatory drug candidate, did not demonstrate a reduction in cardiovascular risk in patients with atherosclerotic cardiovascular disease. The trial, known as the Zeus study, involved over 6,300 participants and was designed to evaluate the drug’s efficacy in reducing major adverse cardiovascular events. The failure of this trial has raised concerns about the company’s ability to expand beyond its current revenue drivers, such as Wegovy and Ozempic. Novo Nordisk stated it remains committed to cardiovascular disease research and will continue two additional trials with ziltivekimab in patients with heart failure and those who have experienced acute heart attacks.
What The Data Shows
Intraday data shows the stock opened at $50.59 and quickly moved lower, reaching a session low of $45.36. Volume has been elevated at 5.8 million shares, which is 0.4 times the 3-month daily average. The stock had been on an upward trend over the past eight sessions, rising from $49.33 to $51.61. The current price of $46.94 places it within the 52-week range of $35.12 to $64.16. The company’s fundamentals remain strong, with a market cap of $226.3 billion, a P/E ratio of 12.2, and a net margin of 37.2%.
What To Watch
Investors should monitor the results of the two ongoing trials with ziltivekimab in heart failure and post-heart attack patients. These trials could provide further insight into the drug’s potential and impact on Novo Nordisk’s long-term strategy in the cardiovascular space.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NVO · Jul 31 session (5-min) · -8.89% vs prior close · updated 8:56 PM ETAI sentiment, last 36h · averaged over 15 stories · 37/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
10d agoStocktwits NewsBEARISH 28Earnings
NVO Stock Slumps After Late-Stage Trial Fails Primary Goal – Retail Says ‘Current Revenue Drivers’ Still Intact
Novo’s Phase 3 trial showed that investigational drug Ziltivekimab did not reduce major adverse cardiovascular events compared with the placebo
10d agoReutersBEARISH 28Product/PR
Novo drug fails to reduce cardiovascular risk in late-stage trial, shares slide
10d agoSeeking AlphaBEARISH 34Product/PR
Novo Nordisk drops as anti-inflammatory drug fails in late-stage trial
Novo Nordisk drops on a late-stage trial setback for the company's anti-inflammatory candidate ziltivekimab in cardiovascular disease. Read more here.
10d agoFinancial TimesBEARISH 34Earnings
Novo Nordisk shares drop 10% after cardiovascular drug trial disappoints
Danish drugmaker has been trying to diversify beyond its blockbuster obesity treatments Wegovy and Ozempic
10d agoQuartzBEARISH 34Product/PR
Novo Nordisk stock sinks after anti-inflammatory heart drug fails late-stage trial
The experimental anti-inflammatory drug ziltivekimab did not reduce major adverse cardiovascular events compared with a placebo in a study of more than 6,300 patients
10d agoTipRanksBEARISH 24Earnings
Novo Nordisk Stock (NVO) Plunges 10% as Weight-Loss Drug Trial Disappoints
Shares of Novo Nordisk ($NVO) are down 10% on July 31 after the European pharmaceutical giant reported disappointing results from its latest weight-loss drug trial....
10d agoMorningstarBEARISH 34Product/PR
Novo Nordisk Shares Drop After Drug Candidate Fails in Cardiovascular Trial
The company said it remains committed to cardiovascular disease and that it plans to continue two additional trials testing ziltivekimab in people with heart failure and in people who suffered an acute heart attack. Results are due in the first half of next year, it added.
10d agoInvesting.com MarketsBEARISH 34General
Why is Novo Nordisk stock plunging today?
Why is Novo Nordisk stock plunging today?
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →